The $900 Million Albertsons Verdict Is $800 Million of Abatement and $100 Million That Can Triple on Appeal

The headline number is $900 million, and it is the largest verdict in Washington state history, according to Attorney General Nick Brown. What the 218-page judgment actually orders is more specific, and stranger, than the round figure suggests.

King County Superior Court Judge Janet M. Helson split the award into two instruments with different legal footing. Albertsons must fund an abatement plan of $800 million, paid into a court-supervised trust, to remedy a public nuisance it created and maintained. It must separately pay $100 million in civil penalties under the Consumer Protection Act.

Then comes the clause that matters most to anyone counting on the money. If the abatement order is reduced or eliminated on appeal, the civil penalty reverts to $337,921,650. The $100 million is not a discount. It is a conditional credit against a much larger penalty, and it survives only as long as the $800 million does.

Two numbers, not one

The distinction is not a lawyer's quibble. Abatement money is forward-looking and supervised: it funds a plan the court retains jurisdiction to enforce, and the court said it will enter further orders implementing that plan. Civil penalties are punitive, discretionary and, in Washington, capped per violation by statute. Mixing them into a single "verdict" figure obscures which part an appellate court can touch and which part is already spoken for.

Albertsons said it was "disappointed by the court's ruling and respectfully disagrees with its conclusions," and that it is reviewing the decision and will "evaluate all available options, including appeal." At trial the company argued that doctors, not pharmacists, were responsible for aggressive opioid prescribing. A company spokesperson said Albertsons is "proud of our pharmacists and their dedication to the patients and communities they serve."

The case, filed in 2022 under then-Attorney General and now Governor Bob Ferguson, originally named several chains. Albertsons was the last defendant standing, because the others either settled early or declared bankruptcy.

Fifty dollars a prescription

The penalty calculation is where the judgment stops reading like a press release. Helson built it from two violation categories, each priced separately.

For distribution, she assessed the statutory maximum of $2,000 for each of 11,953 order lines that Albertsons' own threshold system flagged as suspicious and the company shipped anyway between 2013 and 2016. That is $23,906,000, and Albertsons Companies alone bears it. The court's reasoning was blunt: the company never reported a single order to the Drug Enforcement Administration and never stopped a single shipment, "demonstrating a complete abdication of its duties as a distributor."

For dispensing, she assessed $50 for each of 6,280,313 opioid prescriptions that carried at least one red flag and were filled without documented resolution of that flag. That is $314,015,650. Together the two categories come to $337,921,650, the figure the penalty snaps back to if the abatement falls.

Fifty dollars is a strange number to arrive at by intuition, and the judgment explains where it comes from. Albertsons' own dispensing data record what the patient paid and what third-party payors owed at the time of sale. Across the red-flagged opioid prescriptions the company dispensed in Washington from 2006 through 2022, those amounts total $308,360,088. Applying the 96 percent rate the court accepted, Albertsons took in at least $296,025,684 on prescriptions it filled without documented due diligence.

Divide that by 6,280,313 prescriptions and the average undocumented red-flagged sale comes to about $47.14. The $50 penalty is roughly 106 percent of it. The court said as much in its findings: the penalties are "calculated, in part, to exceed the revenue Albertsons received from the prescriptions it dispensed with unresolved red flags, thereby depriving it of the benefit of its violations." This is disgorgement with a six percent premium attached, not a punishment scaled to harm. The court also declined the state's request for a separate restitution award, folding the unlawful gains into the penalty instead.

Helson went out of her way to be fair on this point, and the fairness cuts against the state. She wrote that while each improperly dispensed red-flagged prescription is a violation, "a substantial portion of those prescriptions likely were legitimate," and that she was taking the already-ordered abatement into account. She also rejected the state's preferred method, which would have priced each of 11,416,788 individual red flags separately with penalties graded by severity, calling that approach more granular than the record warranted. The penalty base the state asked for was nearly twice the one the court used.

Where 96 percent came from

The number that scales the whole dispensing penalty is an extrapolation, and the judgment is unusually explicit about it.

An expert reviewed a sample of 1,200 red-flagged prescriptions drawn from the 6.5 million in Albertsons' Washington data, looking at the electronic notes fields and the hard-copy prescriptions behind them. Of the 1,200, he concluded that 96 percent contained no information documenting resolution of the red flag. The note field specifically was blank 1,104 times out of 1,200. Across all note fields, including prescription, drug-utilization-review and patient-profile notes, 491, or 40.9 percent, were blank or coded "NA."

The blank note fields

A second expert testified that the sample was statistically sound and that a 96 percent rate observed in 1,200 prescriptions would hold across the full population with a confidence interval of 94.73 to 96.98 percent. The court also noted that Albertsons "did not introduce any competent evidence at trial of red-flagged prescriptions for which they did conduct and document due diligence prior to filling."

The population being extrapolated to is large. Albertsons dispensed 10,615,250 opioid prescriptions in Washington from 2006 through 2022, roughly 641 million pills, and its share of the state's dispensing market was 11.4 percent by volume. Of those prescriptions, 6,541,993, or 61.6 percent, bore at least one of fourteen recognized red flags: distance traveled, multiple prescribers, dangerous drug combinations, high dosages, pattern prescribing, early refills, cash payment.

What Albertsons can afford, in the court's own figures

Washington's penalty statute leaves the amount to judicial discretion, and Helson spent several pages establishing that the company could pay. The findings read like a financial statement reproduced in a court filing.

For its fiscal year ended Feb. 28, 2026, Albertsons reported net sales and other revenue of $83.2 billion and adjusted EBITDA of $3.9 billion, the latter calculated without the $773.8 million charge it recorded for its settlement framework with other states, to be paid over nine years. It reported roughly $3.56 billion of available borrowing capacity and spent about $1.49 billion repurchasing its own stock. In January 2023 it paid shareholders a special cash dividend of $6.85 per share, $3,916.9 million, funded in part with $1.4 billion borrowed against its credit facility.

Measured against those figures, $900 million is about 1.1 percent of a single year's revenue and roughly 23 percent of adjusted EBITDA. The court also noted that Albertsons told its own investors the litigation would not be material: its 10-K states management's opinion that any resulting liability, "including any punitive damages, will not have a material adverse effect on the Company's business or overall financial condition."

The company argued the court should look only at pharmacy profitability, which its President of Pharmacy described as margin-diluting and loss-making in most years between 2017 and 2022. Helson rejected that, citing testimony that pharmacy customers shop the store three to four times as often as other customers and spend more on groceries. "It is this more appropriate to consider Albertsons' overall profits, not just the pharmacy profits," she wrote.

The injunction outlasts the check

Money is the part of the judgment that will be litigated. The permanent injunction is the part that binds regardless of what the appellate court does with the arithmetic, and its terms are more specific than the state's press release suggests.

Albertsons is barred from dispensing a covered prescription bearing any of fourteen red flags unless a pharmacist resolves each one first and documents, in a record kept with the prescription, what the flag was and how it was resolved. Covered prescriptions include opioids, benzodiazepines dispensed to anyone who filled an opioid prescription in the prior 30 days, and muscle relaxers for patients with overlapping opioid and benzodiazepine supplies.

The company must build red-flag identification into its dispensing software, require pharmacists to check the state prescription monitoring program before every controlled-substance fill, and staff sufficiently to make that review possible. It must run periodic dispensing reviews at every Washington store, report results to compliance within 30 days, design a system to catch unusual orders if it distributes to its own pharmacies, report suspicious orders to the DEA, and certify compliance under oath annually for five years.

The court ordered all of it because Albertsons, in its view, had not stopped. The findings note that the company still accepts discount cards and cash for controlled substances and "has never integrated a red-flag checklist into its dispensing software or done any monitoring to ensure that documentation of red flags is occurring." Elsewhere the judgment describes Albertsons pharmacies taking patients who were "refugees" from chains that had stopped honoring discount cards, a pharmacist warning that "mistakes can easily be made to put someone's life at risk," and staff describing vomiting from exhaustion and breaking down in tears in the back room. A Safeway employee in North Bend stole more than 70,000 opioid pills over two years before being caught; the state documented thefts of 12,000 pills in Leavenworth and 19,000 in Olympia.

What the appeal will actually argue

Washington skipped the crowd. In April, Albertsons agreed to pay $774 million to settle opioid claims brought by other states and localities. Brown's office declined to join, on the theory that the liability it could prove at trial was worth more than the settlement share on offer. Nine weeks of testimony, 45 witnesses and more than 600 exhibits later, a judge agreed.

The state has now recovered about $2.17 billion for state and local governments from opioid litigation, a figure that includes $47.5 million from Kroger in 2024 and settlements with Walmart, Walgreens and CVS. More than 26,000 Washingtonians have died of an opioid overdose since 1999, and about 7,400 in the last three years.

That is the ledger the money sits against, and it is worth being precise about the scale. Nine hundred million dollars spread across 641 million pills dispensed over seventeen years comes to about $1.40 a pill. The abatement trust is meant to fund opioid addiction treatment and prevention across a state where, by the AG's own arithmetic, roughly ten times as many people were living with opioid use disorder in 2023 as have died since 1999.

Whether any of it arrives depends on an appeal that has not been filed. What the judgment does settle, for now, is a question the settlement wave never answered in public: what a chain's red-flag documentation failure is worth, prescription by prescription, once someone actually counts them.